natgillin/translations-raw huggingface dataset:
Study UX003-CL201 (referred to as Study 201) was a single arm, open-label, dose exploration trial that enrolled three MPS VII patients, ranging in age from 5 years to 25 years. 
Druge študije Študija UX003-CL201 (imenovana študija 201) je bila odprto preskušanje za raziskavo odmerjanja z eno skupino, ki je vključevala tri bolnike z MPS VII, stare od 5 let do 25 let.
Total Mepsevii Dose Range (mg) 
Celotni razpon odmerkov zdravila Mepsevii (mg)
a. Volume (mL) of calculated dose = Total dose (mg) divided by the 2 mg/mL concentration 
a. Volumen (ml) izračunanega odmerka = celotni odmerek (mg), deljen s koncentracijo
Each vial contains 17.8 mg sodium. 
Pomožne snovi z znanim učinkom Ena viala vsebuje 17,8 mg natrija.
The assessment of adverse reactions was based on the exposure of 23 patients from 4 clinical trials, aged 5 months to 25 years, who received vestronidase alfa at doses up to 4 mg/kg once every two weeks for up to 132 weeks. 
Ocena neželenih učinkov je temeljila na izpostavljenosti 23 bolnikov v 4 kliničnih preskušanjih, starih od 5 mesecev do 25 let, ki so do 132 tednov prejemali vestronidazo alfa v odmerkih do 4 mg/kg enkrat na dva tedna.
The infusion was stopped, the patient received anticonvulsants, antipyretics and antibiotics, and the febrile convulsion resolved. 
Vročinski krči so ponehali po ustavitvi infundiranja ter dajanju antikonvulzivov, antipiretikov in antibiotikov.
Discuss with your doctor if the benefits of using Mepsevii are greater than the potential risk to your baby while breast-feeding. 
Pogovorite se z zdravnikom, ali so koristi uporabe zdravila Mepsevii med dojenjem večje od možnih tveganj za vašega otroka.
Each vial of 5 mL concentrate contains 10 mg vestronidase alfa (10 mg/ 5 mL). 
Ena viala s 5 ml koncentrata vsebuje 10 mg vestronidaze alfa (10 mg/5 ml).
Mepsevii 2 mg/mL sterile concentrate vestronidase alfa 
Mepsevii 2 mg/ml, sterilen koncentrat vestronidaza alfa
Patients who were enrolled in Study 301 were eligible to roll over to Study UX003-CL202 (referred to as Study 202), an open-label extension trial in which patients received additional doses of vestronidase alfa at 4 mg/kg intravenously every other week for up to 144 weeks. 
Bolniki, ki so sodelovali v študiji 301, so lahko prešli na odprto podaljšanje preskušanja UX003-CL202 (študija 202), v katerem so do 144 tednov vsak drugi teden prejemali dodatne intravenske odmerke vestronidaze alfa 4 mg/kg.
How Mepsevii works 
Kako deluje zdravilo Mepsevii
Dilute the calculated dose 1:1 using equal volume of sodium chloride 9 mg/mL (0.9%) solution for injection for intravenous infusion. 
Izračunani odmerek razredčite v razmerju 1 : 1 z enako količino 0,9-odstotne raztopine natrijevega klorida (9 mg/ml) za intravensko infuzijo.
It is not known whether vestronidase alfa is excreted in human milk, but systemic exposure via breast-milk is not expected. 
Podatkov iz študij pri doječih ženskah ni. Ni znano, ali se vestronidaza alfa izloča v materino mleko, vendar se ne pričakuje, da bo prek materinega mleka prišlo do sistemske izpostavljenosti.
Your doctor may also give (or have given) you other medicines to manage the allergic reaction such as an antihistamine or corticosteroid or an antipyretic, a medicine to reduce fever. 
Zdravnik vam bo morda dal (ali vam je že dal) tudi druga zdravila, denimo antihistaminik ali kortikosteroid za zdravljenje alergijske reakcije ali antipiretik za znižanje zvišane telesne temperature.
Slowly withdraw Mepsevii from the appropriate number of vials using caution to avoid excessive agitation and any air or frothing. 
Počasi odvzemite zdravilo Mepsevii iz ustreznega števila vial ter pazite, da vial ne stresate preveč in da se vsebina ne peni.
Key Secondary Endpoint: Multi-Domain Clinical Responder Index (MDRI) 
Ključni sekundarni opazovani dogodek je bil večdomenski indeks kliničnega odziva (MDRI), sestavljen iz šestih domen
The pharmacokinetics of vestronidase alfa were evaluated in a total of 19 MPS VII patients including 15 paediatric patients and 4 adults from 3 clinical trials. 
Farmakokinetiko vestronidaze alfa so ocenili pri skupaj 19 bolnikih z MPS VII, vključno s
*Vestronidase alfa is a recombinant form of human beta-glucuronidase (rhGUS) and is produced in Chinese Hamster Ovary cell culture by recombinant DNA technology. 
* Vestronidaza alfa je rekombinantna oblika humane beta-glukuronidaze (rhGUS).
Rentschler Biopharma SE Erwin-Rentschler-Strasse 21 88471 Laupheim Germany 
Erwin-Rentschler-Strasse 21
Patients should be observed for a minimum of 60 minutes after completing the infusion of vestronidase alfa. 
Po koncu infundiranja vestronidoze alfa je treba bolnike opazovati še najmanj 60 minut.
Other Investigations 
DRUGI PODATKI
Your doctor may give (or have given) you other medicines to manage the allergic reaction such as an antihistamine or corticosteroid or an antipyretic, a medicine to reduce fever. 
- Zdravnik vam bo morda dal (ali vam je že dal) še druga zdravila, denimo antihistaminik ali kortikosteroid za zdravljenje alergijske reakcije ali antipiretik za znižanje zvišane telesne temperature.
Mepsevii 2 mg/mL concentrate for solution for infusion. 
Mepsevii 2 mg/ml koncentrat za raztopino za infundiranje
Do not use if the solution is discoloured or if there is particulate matter in the solution. 
Raztopine ne uporabljajte, če je drugačne barve ali če vsebuje tujke.
Minimal important differences (MIDs) were pre-specified for the six MDRI domains plus fatigue, which are: 6MWT (≥23 meters and ≥10% change from baseline), FVC (5% absolute change or 10% relative change from baseline in FVC%pred), shoulder flexion (20 degree change of both shoulder range of motion), visual acuity (3 lines (corrected, both eyes), BOT-2 fine motor (fine motor precision: change of 0.72, and manual dexterity: change of 1.47), BOT-2 gross motor (balance: 0.57, and running speed and agility: 0.59), and fatigue (10 points of total score). 
(sprememba območja gibanja obeh ramen za 20 stopinj), ostrina vida (3 linije (korigirano za obe očesi)), fine motorične spretnosti BOT-2 (natančnost fine motorike: sprememba za 0,72; ročna spretnost: sprememba za 1,47), grobe motorične spretnosti BOT 2 (ravnotežje: 0,57; hitrost in gibljivost pri teku: 0,59) ter utrujenost (celotni rezultat 10 točk).
The primary endpoint was the percent reduction in urinary GAG excretion (Dermatan Sulfate, DS) before and after 24 weeks of treatment with vestronidase alfa. 
Primarni opazovani dogodek je bil odstotek zmanjšanja izločanja GAG z urinom (dermatansulfat, DS)
This event was assessed as possibly related to vestronidase alfa due to the temporal association with the infusion. 
Zaradi časovne povezave z infuzijo je ta dogodek ocenjen kot morebiti povezan z vestronidazo alfa.
Serious hypersensitivity reactions, including anaphylaxis, have been reported with vestronidase alfa; therefore, appropriate medical support should be readily available when vestronidase alfa is administered. 
Preobčutljivostne reakcije, vključno z anafilaksijo Pri uporabi vestronidaze alfa so poročali o resnih preobčutljivostnih reakcijah, vključno z anafilaksijo;
MedDRA Preferred Term 
Prednostni izraz (MedDRA)
- You may have side effects while you are being given Mepsevii or for up to a day afterwards. 
- Med prejemanjem zdravila Mepsevii ali v enem dnevu po njem se lahko pri vas pojavijo neželeni učinki.
After 24 weeks of treatment with vestronidase alfa, a rapid and sustained, highly significant reduction in uGAG (DS) excretion was achieved with a LS mean (±SE) percentage change of -64.82% (±2.468%) (p<0.0001). 
Po 24 tednih zdravljenja z vestronidazo alfa je bilo doseženo hitro, trajno in zelo pomembno zmanjšanje izločanja uGAG (DS) z odstotno spremembo v mediani najmanjših kvadratov
Mepsevii 2 mg/mL concentrate for solution for infusion vestronidase alfa 
Mepsevii 2 mg/ml koncentrat za raztopino za infundiranje vestronidaza alfa
Urticaria Rash Pruritus 
- koprivnica (urtikarija)
Total Number of Mepsevii Vials 
Celotno število vial zdravila Mepsevii
After repeated dosing of 4 mg/kg every other week in MPS VII patients, the mean ± standard deviation of the total clearance (CL) was 0.079 ± 0.045 L/h/kg (range: 0.038 to 0.20 L/h/kg); the mean ± standard deviation of the elimination half-life (t1/2) was 2.6 ± 0.6 hours (range: 0.9 to 3.6 hours). 
Po ponavljajočem se odmerjanju 4 mg/kg vsak drugi teden pri bolnikih z MPS VII je bil srednji ± standardni odklon v skupnem očistku (CL) 0,079 ± 0,045 l/h/kg (razpon: od 0,038 do 0,20 l/h/kg);
Table 1 Adverse reactions reported in patients treated with Mepsevii MedDRA System Organ Class 
Preglednica 1 Neželeni učinki, o katerih so poročali pri bolnikih, zdravljenih z zdravilom
Common *Refer to description of selected adverse reactions for details on the febrile convulsion reported in 1 of 23 trial patients. 
* Glejte opis izbranih neželenih učinkov za podrobnosti o vročinskih krčih, o katerih so poročali pri
Description of selected adverse reactions 
Opis izbranih neželenih učinkov Vročinski krči
IV use after dilution 
Za IV uporabo po razredčitvi.
If not used immediately, in-use storage times and conditions prior to use are the responsibility of the user, but should normally not be longer than 36 hours at 2°C - 8°C followed by up to 6 hours at room temperature up to a maximum of 25°C. 
Zdravilo se praviloma sme shraniti za največ 36 ur pri temperaturi 2-8 °C in nato za največ 6 ur pri sobni temperaturi, ki ne sme presegati 25 °C.
How to store Mepsevii 
Kako boste dobili zdravilo Mepsevii
Each vial of 5 mL concentrate contains 10 mg vestronidase alfa. 
Ena viala s 5 ml koncentrata vsebuje 10 mg vestronidaze alfa.
Slowly add Mepsevii to the infusion bag using care to avoid agitation, ensuring liquid to liquid contact without generating bubbles or turbulence. 
Tekočini se morata zmešati, ne da bi prišlo do mehurčkov ali turbulence.
Mepsevii is considered high in sodium. 
Zdravilo Mepsevii velja za zdravilo z visoko vsebnostjo natrija.
Each mL of concentrate contains 2 mg vestronidase alfa*. 
En ml koncentrata vsebuje 2 mg vestronidaze alfa*.
Posology 
Koprivnica
The clinical program for vestronidase alfa included 23 treatment naïve patients with MPS VII from 4 clinical trials, aged 5 months to 25 years, who received vestronidase alfa at doses up to 4 mg/kg once every two weeks for up to 132 weeks. 
starih od 5 mesecev do 25 let, z MPS VII v 4 kliničnih preskušanjih, ki so do 132 tednov prejemali vestronidazo alfa v odmerkih do 4 mg/kg enkrat na dva tedna.
This medicinal product contains 17.8 mg sodium per vial and is administered in sodium chloride 9 mg/mL (0.9%) solution for infusion (see section 6.6). 
Dieta z omejitvijo natrija To zdravilo vsebuje 17,8 mg natrija na vialo in se daje v 0,9-odstotni raztopini natrijevega klorida
Each mL of sterile concentrate contains 2 mg vestronidase alfa. 
En ml sterilnega koncentrata vsebuje 2 mg vestronidaze alfa.
Each mL of concentrate contains 2 mg vestronidase alfa. 
En ml koncentrata vsebuje 2 mg vestronidaze alfa.
Common side effects (may affect up to 1 in 10 people): - Itching of the skin (pruritus) - Loose stools (diarrhoea) - Rash - Fever with involuntary contractions of muscles of face or limbs (febrile convulsion) 
- izpuščaj - zvišana telesna temperatura z nehotenim krčenjem mišic obraza ali okončin (vročinski krči)
Study UX003-CL203 (referred to as Study 203) is an ongoing open-label, uncontrolled single arm study that enrolled eight patients less than 5 years of age at a dose of 4 mg/kg vestronidase alfa every two weeks for 48 weeks of treatment period and additional weeks during optional continuation period to evaluate reduction of urinary GAG excretion, growth velocity and hepatosplenomegaly. 
V njej sodeluje 8 bolnikov, mlajših od 5 let, ki so v obdobju zdravljenja 48 tednov dobivali vestronidazo alfa v odmerku 4 mg/kg na vsaka dva tedna in imajo možnost dodatnih tednov izbirnega podaljšanja zdravljenja.
The risks and benefits of readministering vestronidase alfa should be considered following a severe hypersensitivity reaction. 
Po hudi preobčutljivostni reakciji je treba pretehtati tveganja in koristi ponovnega zdravljenja z vestronidazo alfa.
Colourless to slightly yellow solution. 
koncentrat za raztopino za infundiranje (sterilen koncentrat) Brezbarvna do rahlo rumena raztopina.
Talk to your doctor before you are given Mepsevii. 
Preden dobite zdravilo Mepsevii, se posvetujte z zdravnikom.
Febrile Convulsion 
Bolezni živčevja
Special populations 
Posebne skupine bolnikov Starejši bolniki
Clinical efficacy and safety 
KLINIČNI PODATKI
After the injection, the pressure within the eye should be checked. 
Po injiciranju je treba preveriti tlak v očesu.
Further information on Eylea can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports. 
Nadaljnje informacije za zdravilo Eylea so na voljo na spletni strani agencije: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
The diseases cause the gradual loss of the central part of a person's vision. 
Bolezen povzroči postopno izgubo osrednjega dela vida.
Eylea received a marketing authorisation valid throughout the EU on 22 November 2012. 
Za zdravilo Eylea je bilo 22. novembra 2012 izdano dovoljenje za promet, veljavno po vsej EU.
It can also attach to other proteins such as placental growth factor (PlGF). 
Veže se lahko tudi na druge beljakovine, kot je placentni rastni dejavnik (PlGF).
What measures are being taken to ensure the safe and effective use of Eylea? 
Kateri ukrepi se izvajajo za zagotovitev varne in učinkovite uporabe zdravila Eylea?
Therefore, the Agency decided that Eylea's benefits are greater than its risks and it can be authorised for use in the EU. 
Agencija je zaključila, da so koristi zdravila Eylea večje od z njim povezanih tveganj in da se lahko odobri za uporabo v EU.
The macula provides central vision that is needed to see detail for everyday tasks such as driving, reading and recognising faces. 
Rumena pega zagotavlja osrednji vid, ki je potreben za zaznavanje podrobnosti med vsakdanjimi opravili, na primer pri vožnji avtomobila, branju in prepoznavanju obrazov.
How often the injections are given depends on the condition being treated and the response of the patient to treatment. 
Pogostost dajanja injekcije je odvisna od bolezni, ki jo zdravimo, in odziva bolnika na zdravljenje.
Both studies also looked at the maintenance of the effect in the second year of treatment, during which the number of injections and the time between injections were adjusted depending on the vision and changes within the eye. 
V obeh študijah so proučevali tudi vzdrževanje tega učinka v drugem letu zdravljenja, med katerim sta bila število injekcij in časovni razmik med posameznimi injekcijami prilagojena glede na vid in spremembe znotraj očesa.
The Agency further noted that there were no major or unexpected safety concerns with Eylea. 
Nadalje je agencija ugotovila, da ni večjih ali nepričakovanih pomislekov glede varnosti pri uporabi zdravila Eylea.
As for all medicines, data on the use of Eylea are continuously monitored. 
Tako kot za vsako zdravilo se tudi podatki o uporabi zdravila Eylea stalno spremljajo.
What benefits of Eylea have been shown in studies? 
Kakšne koristi zdravila Eylea so se pokazale v študijah?
An overview of Eylea and why it is authorised in the EU 
Pregled zdravila Eylea in zakaj je odobreno v EU
Other information about Eylea 
Druge informacije o zdravilu Eylea
By blocking these factors, aflibercept reduces the growth of the blood vessels and controls the leakage and swelling. 
Aflibercept z zaviranjem teh dejavnikov zmanjšuje rast krvnih žil ter nadzoruje iztekanje iz njih in otekanje.
Why is Eylea authorised in the EU? 
Zakaj je bilo zdravilo Eylea odobreno v EU?
Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Eylea have also been included in the summary of product characteristics and the package leaflet. 
Priporočila in previdnostni ukrepi, ki jih morajo za varno in učinkovito uporabo zdravila Eylea upoštevati zdravstveni delavci in bolniki, so vključeni tudi v povzetek glavnih značilnosti zdravila in navodilo za uporabo.
Side effects reported with Eylea are carefully evaluated and any necessary action taken to protect patients. 
Neželeni učinki, o katerih so poročali pri zdravilu Eylea, se skrbno ovrednotijo in po potrebi se sprejmejo ukrepi za zaščito bolnikov.
This effect was maintained at 52 weeks, despite less frequent administration of Eylea between week 24 and 52. 
Učinki so bili vidni še v 52. tednu kljub manj pogostim injekcijam zdravila Eylea med 24. in 52. tednom.
The pre-filled syringe contains more than the recommended dose, therefore when preparing the injection, the doctor must expel the excess volume from the syringe and ensure the injection of the correct dose. 
Napolnjena injekcijska brizga vsebuje večji odmerek od priporočenega, zato mora zdravnik pri pripravi injekcije iztisniti odvečno količino iz brizge in zagotoviti injiciranje ustreznega odmerka.
Eylea is a medicine used to treat adults with: 
Zdravilo Eylea je zdravilo za zdravljenje odraslih bolnikov z:
What is Eylea and what is it used for? 
Kaj je zdravilo Eylea in za kaj se uporablja?
The company that markets Eylea will provide up-to-date educational material for doctors (to minimise the risks associated with the injection in the eye) and for patients (so they can recognise any serious side effects, and know when to seek urgent attention from their doctor). 
Podjetje, ki trži zdravilo Eylea, bo zagotovilo izobraževalno gradivo za zdravnike (da bi tako čim bolj zmanjšali tveganja, povezana z injiciranjem v oko) in bolnike (da bi lahko prepoznali morebitne resne neželene učinke in tako vedeli, kdaj naj poiščejo nujno pomoč pri zdravniku).
During the second year of treatment, the effectiveness was generally maintained, with a majority of patients receiving injections at an extended dosing interval of 10 weeks, although a small number of patients occasionally needed more frequent injections (such as monthly). 
Med drugim letom zdravljenja je učinkovitost na splošno ostala enaka, pri čemer je večina bolnikov prejemala injekcije v daljšem desettedenskem razmiku odmerjanja, manjše število bolnikov pa je občasno potrebovalo pogostejše injiciranje (na primer vsak mesec).
• impaired vision due to macular oedema caused by diabetes; 
• okvaro vida zaradi makularnega edema, ki ga povzroča sladkorna bolezen;
Eylea is given as an injection of 2 mg into the affected eye, repeated as appropriate at intervals of a month or more. 
Zdravilo Eylea se daje kot injekcija 2 mg v prizadeto oko, po potrebi s ponavljanjem v razmikih enega meseca ali več.
What are the risks associated with Eylea? 
Kakšna tveganja so povezana z zdravilom Eylea?
Eylea was either given once a month, or once every other month after the first five monthly injections. 
Zdravilo Eylea so bolniki prejemali bodisi enkrat na mesec bodisi vsak drugi mesec po prejetju petih mesečnih injekcij.
In contrast, in patients given laser treatment the improvement after a year was only about 1 letter. 
Za primerjavo se je stanje pri bolnikih, ki so prejeli lasersko zdravljenje, po enem letu izboljšalo samo za okoli eno črko.
For more information about how Eylea is used, see the package leaflet or contact your doctor or pharmacist. 
Za več informacij glede uporabe zdravila Eylea glejte navodilo za uporabo ali se posvetujte z zdravnikom ali farmacevtom.
Eylea was shown to be as effective as ranibizumab in maintaining vision in patients with wet AMD: looking at the results of the two studies together, the proportions of patients who maintained vision were 96.1% (517 out of 538), 95.4% (533 out of 559) and 95.3% (510 out of 535) for 0.5 mg Eylea every four weeks, 2 mg Eylea every four weeks and 2 mg Eylea every eight weeks, respectively, compared with 94.4% (508 out of 538) of patients treated with ranibizumab every four weeks. 
Glede na rezultate obeh študij skupaj je bil delež bolnikov, ki so ohranili vid, 96,1 % (517 od 538 bolnikov) pri injiciranju 0,5 mg zdravila Eylea vsake štiri tedne, 95,4 % (533 od 559 bolnikov) pri injiciranju 2 mg zdravila Eylea vsake štiri tedne in 95,3 % (510 od 535 bolnikov) pri injiciranju 2 mg zdravila Eylea vsakih osem tednov v primerjavi s 94,4 % (508 od 538) bolnikov, zdravljenih z ranibizumabom vsake štiri tedne.
• impaired vision due to myopic choroidal neovascularisation (a severe type of short-sightedness where the eyeball continues to grow, becoming longer than it should be). 
• okvaro vida zaradi miopične horoidalne neovaskularizacije, ki jo povzroča kratkovidnost (resna oblika kratkovidnosti, pri kateri zrklo še naprej raste in postane daljše, kot bi smelo biti).
Eylea contains the active substance aflibercept. 
Zdravilo Eylea vsebuje učinkovino aflibercept.
The main measure of effectiveness was the proportion of patients who maintained vision (defined as losing less than 15 letters in a standard eye test) after the first year of treatment. 
Glavno merilo učinkovitosti je bilo delež bolnikov, ki so ohranili vid (kar je bilo opredeljeno kot zmanjšanje števila pravilno prebranih črk za manj kot 15 črk pri standardnem očesnem testu) po prvem letu zdravljenja.
These compared monthly injections of Eylea 2 mg with a sham injection using a syringe without a needle. 
V teh so primerjali mesečno injiciranje zdravila Eylea v odmerku 2 mg z injekcijo placeba, pri kateri se uporabi brizga brez igle.
Aflibercept is an engineered protein that has been designed to attach to and block the effects of a substance called vascular endothelial growth factor A (VEGF-A). 
Aflibercept je umetno ustvarjena beljakovina, ki je bila zasnovana tako, da se veže na snov, imenovano žilni endotelijski rastni dejavnik A (VEGF-A), in zavira njene učinke.
The benefit was largely maintained with as-needed treatment up to 52 weeks, although some of the benefit seemed to be lost when patients were treated and followed up for longer periods than this. 
Pri zdravljenju po potrebi so se koristni učinki večinoma ohranili do 52 tednov, čeprav se je pri zdravljenju in spremljanju bolnikov v obdobju, daljšem od tega, zdelo, da so se nekatere koristi izgubile.
Two further main studies involving 872 patients with diabetic macular oedema looked at the effect of Eylea compared with laser treatment. 
V dveh dodatnih študijah, v kateri je bilo vključenih 872 bolnikov z makularnim edemom, ki ga povzroča sladkorna bolezen, so proučevali učinke zdravila Eylea v primerjavi z laserskim zdravljenjem.
Myopic choroidal neovascularisation 
Miopična horoidalna neovaskularizacija
Subsequent results from a supportive study indicated the effectiveness of extended treatment intervals in patients with wet AMD. 
Poznejši rezultati iz podporne študije so pokazali učinkovitost podaljšanih razmikov zdravljenja pri bolnikih z vlažno obliko starostne degeneracije rumene pege.
The studies compared Eylea (given either as 0.5 mg every four weeks, 2 mg every four weeks or 2 mg every eight weeks, all after three initial monthly doses) with ranibizumab, another treatment for AMD which was given by injection into the eye every four weeks. 
V študijah so zdravilo Eylea (dano bodisi v odmerku 0,5 mg vsake štiri tedne, 2 mg vsake štiri tedne ali 2 mg vsakih osem tednov, v vseh primerih po treh začetnih mesečnih odmerkih) primerjali z ranibizumabom, drugo obliko zdravljenja starostne degeneracije rumene pege, ki se daje z injiciranjem v oko vsake štiri tedne.
Eylea is available as prefilled syringes or vials containing a solution for intravitreal injection (injection into the vitreous humour, the jelly-like fluid inside the eye). 
Zdravilo Eylea je na voljo v obliki napolnjenih injekcijskih brizg ali vial, ki vsebujejo raztopino za intravitrealno injiciranje (injiciranje v steklovino, želatini podobno tekočino v očesu).
The pre-filled syringe and the vial are for single use only. 
Napolnjena injekcijska brizga in viala sta le za enkratno uporabo.